Preclinical Investigations on Anti-fibrotic Potential of Long-Term Oral Therapy of Sodium Astragalosidate in Animal Models of Cardiac and Renal Fibrosis-Reference-Cited by-同舟云学术

Preclinical Investigations on Anti-fibrotic Potential of Long-Term Oral Therapy of Sodium Astragalosidate in Animal Models of Cardiac and Renal Fibrosis

Published:2024-01-12 Issue:2 Volume:7 Page:421-431
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Chen Xiao-Yi¹²^ORCID,Wang Tian-Tian¹³,Shen Qing¹⁴^ORCID,Ma Hao¹,Li Zhan-Hua¹,Yu Xi-Na¹,Huang Xiao-Feng³,Qing Lin-Sen³^ORCID,Luo Pei¹^ORCID

Affiliation:

1. State Key Laboratories for Quality Research in Chinese Medicines, Faculty of Pharmacy, Macau University of Science and Technology, Macau 999078, China

2. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China

3. Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China

4. Collaborative Innovation Center of Seafood Deep Processing, Zhejiang Province Joint Key Laboratory of Aquatic Products Processing, Institute of Seafood, Zhejiang Gongshang University, Hangzhou 310012, China

Funder

Science and Technology Department of Sichuan Province

Chinese Academy of Sciences

Macao Youth Scholars Program

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.3c00264

Reference38 articles.

1. Cellular Mechanisms of Tissue Fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis

2. Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers

3. Switch over from intravenous to oral therapy: A concise overview

4. Idiopathic pulmonary fibrosis

5. Traditional Chinese medicine as a therapeutic option for cardiac fibrosis: Pharmacology and mechanisms